Three polymorphisms in cytochrome P450 1B1 (CYP1B1) gene and breast cancer risk: a meta-analysis

Economopoulos, KP; Sergentanis, TN

dc.contributor.author	Economopoulos, KP	en
dc.contributor.author	Sergentanis, TN	en
dc.date.accessioned	2014-03-01T02:00:47Z
dc.date.available	2014-03-01T02:00:47Z
dc.date.issued	2010	en
dc.identifier.issn	0167-6806	en
dc.identifier.uri	https://dspace.lib.ntua.gr/xmlui/handle/123456789/29134
dc.subject	CYP1B1	en
dc.subject	Cytochrome P450	en
dc.subject	Polymorphism	en
dc.subject	Breast cancer	en
dc.subject	Arg48Gly	en
dc.subject	Ala119Ser	en
dc.subject	Asn453Ser	en
dc.subject.classification	Oncology	en
dc.subject.other	POLYCYCLIC AROMATIC-HYDROCARBONS	en
dc.subject.other	SEX-HORMONE METABOLISM	en
dc.subject.other	ESTROGEN-METABOLISM	en
dc.subject.other	MAMMOGRAPHIC DENSITY	en
dc.subject.other	POSTMENOPAUSAL WOMEN	en
dc.subject.other	P450 1A1	en
dc.subject.other	ASSOCIATION	en
dc.subject.other	VARIANTS	en
dc.subject.other	PATHWAY	en
dc.subject.other	SUSCEPTIBILITY	en
dc.title	Three polymorphisms in cytochrome P450 1B1 (CYP1B1) gene and breast cancer risk: a meta-analysis	en
heal.type	journalArticle	en
heal.language	English	en
heal.publicationDate	2010	en
heal.abstract	Cytochrome P450 1B1 (CYP1B1) is a P450 enzyme implicated in the metabolism of exogenous and endogenous substrates. The metabolism of polycyclic aromatic hydrocarbons and other procarcinogens through CYP1B1 may well lead to their activation. Apart from the extensively studied Val432Leu polymorphism, three single nucleotide polymorphisms in CYP1B1 have been studied concerning their potential implication in terms of breast cancer risk: Arg48Gly, Ala119Ser and Asn453Ser. This meta-analysis aims to examine whether the three aforementioned polymorphisms are associated with breast cancer risk. Eligible articles were identified by a search of MEDLINE bibliographical database for the period up to December 2009. Concerning Arg48Gly polymorphism, 10 studies were eligible (11,321 cases and 13,379 controls); 11 studies were eligible for Ala119Ser (10,715 cases and 11,678 controls); 12 cases were eligible regarding Asn453Ser (11,630 cases and 14,053 controls). Pooled odds ratios (OR) were appropriately derived form fixed-effects or random-effects models. Sensitivity analysis excluding studies whose genotype frequencies in controls significantly deviated from Hardy-Weinberg equilibrium was performed. Concerning Arg48Gly, the pooled ORs (95% CI) were 0.933 (0.808-1.078) for heterozygous and 0.819 (0.610-1.100) for homozygous Gly subjects. Regarding Ala119Ser, the pooled ORs were 0.992 (0.896-1.097) for heterozygous and 0.935 (0.729-1.198) for homozygous Ser subjects. With respect to Asn453Ser, the pooled ORs were 0.961 (0.906-1.019) for heterozygous and 0.984 (0.846-1.144) for homozygous Ser subjects. In conclusion, this meta-analysis suggests that CYP1B1 Arg48Gly, Ala119Ser and Asn453Ser polymorphisms are not associated with breast cancer risk. Studies on Chinese populations are needed, to elucidate race-specific effects on East Asian populations, if any.	en
heal.publisher	SPRINGER	en
heal.journalName	BREAST CANCER RESEARCH AND TREATMENT	en
dc.identifier.isi	ISI:000278810700026	en
dc.identifier.volume	122	en
dc.identifier.issue	2	en
dc.identifier.spage	545	en
dc.identifier.epage	551	en